Clinical Trials
13 trialsNCT03314740 2025-01-10
BAROCCO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT03117933 2024-01-23
OCTOVA
University of Oxford
Phase 2 Completed
NCT02681237 2022-05-09
A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer
University Health Network, Toronto
Phase NA Completed
NCT02889900 2022-03-08
CONCERTO
AstraZeneca
Phase 2 Completed
NCT02855697 2022-02-22
MOLTO
The Christie NHS Foundation Trust
Phase EARLY_PHASE1 Completed
NCT01065662 2021-04-21
AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01132820 2019-08-08
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00278343 2018-08-29
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02340611 2018-06-12
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib
University Health Network, Toronto
Phase 2 Completed
NCT00275028 2015-11-09
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01131234 2014-12-23
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01229930 2013-08-26
Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00475956 2010-04-15
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed